Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Profit After Tax (2019 - 2025)

Historic Profit After Tax for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$82.2 million.

  • Kymera Therapeutics' Profit After Tax fell 3150.74% to -$82.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.1 million, marking a year-over-year decrease of 7621.96%. This contributed to the annual value of -$223.9 million for FY2024, which is 5232.37% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Profit After Tax stood at -$82.2 million, which was down 3150.74% from -$76.6 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Profit After Tax high stood at -$13.1 million for Q1 2021, and its period low was -$82.2 million during Q3 2025.
  • Moreover, its 5-year median value for Profit After Tax was -$40.9 million (2023), whereas its average is -$44.7 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first soared by 5878.96% in 2023, then crashed by 39242.76% in 2024.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Profit After Tax stood at -$33.9 million in 2021, then dropped by 2.85% to -$34.9 million in 2022, then skyrocketed by 58.79% to -$14.4 million in 2023, then crashed by 392.43% to -$70.8 million in 2024, then dropped by 16.15% to -$82.2 million in 2025.
  • Its Profit After Tax was -$82.2 million in Q3 2025, compared to -$76.6 million in Q2 2025 and -$65.6 million in Q1 2025.